221 related articles for article (PubMed ID: 20154618)
21. Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.
Kim BJ; Kim JH; Kim HS; Zang DY
Oncotarget; 2017 Feb; 8(8):13979-13985. PubMed ID: 28103578
[TBL] [Abstract][Full Text] [Related]
22. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
23. Hereditary kidney cancer: unique opportunity for disease-based therapy.
Linehan WM; Pinto PA; Bratslavsky G; Pfaffenroth E; Merino M; Vocke CD; Toro JR; Bottaro D; Neckers L; Schmidt LS; Srinivasan R
Cancer; 2009 May; 115(10 Suppl):2252-61. PubMed ID: 19402075
[TBL] [Abstract][Full Text] [Related]
24. [50 years of renal cell carcinoma].
Doehn C
Aktuelle Urol; 2019 Aug; 50(4):378-385. PubMed ID: 31398756
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Igarashi H; Esumi M; Ishida H; Okada K
Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
[TBL] [Abstract][Full Text] [Related]
26. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.
Cowey CL; Rathmell WK
Curr Oncol Rep; 2009 Mar; 11(2):94-101. PubMed ID: 19216840
[TBL] [Abstract][Full Text] [Related]
27. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
[TBL] [Abstract][Full Text] [Related]
28. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
Pantuck AJ; Zeng G; Belldegrun AS; Figlin RA
Clin Cancer Res; 2003 Oct; 9(13):4641-52. PubMed ID: 14581333
[TBL] [Abstract][Full Text] [Related]
29. [Heredity in renal and prostatic neoplasia].
Prayer Galetti T; D'Arrigo L; De Zorzi L; Patarnello T
Arch Ital Urol Androl; 1997 Sep; 69(4):241-6. PubMed ID: 9417296
[TBL] [Abstract][Full Text] [Related]
30. Gene therapy for renal cancer.
Haviv YS; Curiel DT
Contrib Nephrol; 2008; 159():135-150. PubMed ID: 18391590
[TBL] [Abstract][Full Text] [Related]
31. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
32. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management.
Maher ER
World J Urol; 2018 Dec; 36(12):1891-1898. PubMed ID: 29680948
[TBL] [Abstract][Full Text] [Related]
33. Genetic evaluation of von Hippel-Lindau disease for early diagnosis and improved prognosis.
Akcaglar S; Yavascaoglu I; Vuruskan H; Oktay B
Int Urol Nephrol; 2008; 40(3):615-20. PubMed ID: 18074239
[TBL] [Abstract][Full Text] [Related]
34. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma.
Yao M; Yoshida M; Kishida T; Nakaigawa N; Baba M; Kobayashi K; Miura T; Moriyama M; Nagashima Y; Nakatani Y; Kubota Y; Kondo K
J Natl Cancer Inst; 2002 Oct; 94(20):1569-75. PubMed ID: 12381710
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Martinez Chanza N; Tripathi A; Harshman LC
Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
[TBL] [Abstract][Full Text] [Related]
36. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
[TBL] [Abstract][Full Text] [Related]
37. The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.
Hu SL; Chang A; Perazella MA; Okusa MD; Jaimes EA; Weiss RH;
J Am Soc Nephrol; 2016 Aug; 27(8):2227-37. PubMed ID: 26961346
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
39. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene.
Chen F; Kishida T; Duh FM; Renbaum P; Orcutt ML; Schmidt L; Zbar B
Cancer Res; 1995 Nov; 55(21):4804-7. PubMed ID: 7585510
[TBL] [Abstract][Full Text] [Related]
40. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER
Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
